BioCentury | Aug 9, 2019
Company News

Aug. 8 Company Quick Takes: Amarin tumbles on Vascepa update; plus Alexandria, Cambrex, Kala and miRagen

...cash runway into 2Q20. Targets: miR-29 - MicroRNA-29; miR-92a - MicroRNA-92a; miR-155 - MicroRNA-155; BioCentury Staff Cobomarsen (MRG-106) Inveltys...
BioCentury | Oct 21, 2017
Product Development

Naked ambition

...or vehicle. On Oct. 13, miRagen reported interim data from a Phase I trial of MRG-106...
...months or longer. Patients received 300, 600 or 900 mg doses of subcutaneous or IV MRG-106...
...patient who had a grade 3 worsening of pruritus that may have been related to MRG-106...
BioCentury | Oct 20, 2017
Clinical News

miRagen reports Phase I data of systemic microRNA therapy in CTCL

...showing that once-weekly 300, 600 and 900 mg doses of systemically administered subcutaneous or IV MRG-106...
...skin disease severity over a patient’s entire body. Additionally, 9 of 13 patients who received MRG-106...
...maximal improvement in mSWAT score, and 5 patients maintained a durable response for ≥4 months. MRG-106...
BioCentury | Oct 13, 2017
Clinical News

miRagen reports systemic microRNA therapy data in CTCL

...NASDAQ:MGEN) reported interim data from the second part of an ongoing Phase I trial of MRG-106...
...entire body. miRagen said the magnitude of improvement appeared to correlate with the duration of MRG-106...
...of subcutaneous or IV MRG-106, a synthetic microRNA antagonist of microRNA-155 . All doses of MRG-106...
BioCentury | Nov 3, 2016
Company News

Signal, miRagen deal

...company, while the investor syndicate will own 27% and Signal's shareholders will own 4%. miRagen’s MRG-106...
...Boulder, Colo. Signal Genetics Inc. (NASDAQ:SGNL), New York, N.Y. Business: Cancer, Cardiovascular, Neurology Jaime De Leon MRG-106 MRG-201 miRagen...
BioCentury | Nov 1, 2016
Company News

miRagen finds public path via Signal merger

...the combined company, while the investor syndicate will own 27% and Signal's shareholders 4%. miRagen’s MRG-106...
...being evaluated to treat pathological fibrosis. Signal gained $0.14 (38%) to $0.50 on Tuesday. Jaime De Leon MRG-106 MRG-201 Myeloma...
BioCentury | Sep 22, 2016
Distillery Therapeutics

Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); microRNA-155 (miR-155)

...could include identifying and testing miR-155 inhibitors in models of leishmaniasis. miRagen Therapeutics Inc. has MRG-106...
BioCentury | Mar 7, 2016
Clinical News

MRG-106: Phase I started

...miRagen began an open-label, U.S. Phase I trial of MRG-106 in about 25 patients. The first...
...in about 25 patients. The first part will evaluate up to 5 intratumoral injections of MRG-106...
...9 subcutaneous injections of MRG-106 over 26 days. miRagen Therapeutics Inc. , Boulder, Colo. Product: MRG-106...
BioCentury | Nov 11, 2015
Financial News

miRagen raises $41 series C

...will use the proceeds to put two products into the clinic this year. These include MRG-106...
Items per page:
1 - 9 of 9